Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients post renal transplantatio
Not Applicable
Recruiting
- Conditions
- Diabetic patients after kidney transplant
- Registration Number
- JPRN-UMIN000033628
- Lead Sponsor
- Tokyo Women's Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with a history of hypersensitivity to components of SGLT2 inhibitors 2. Type 1 diabetes 3. Patients with postoperative ureteral stenosis such as ureteral stent placement 4. Patients with a history of repeated pyelonephritis 5. Patients with severe ketosis or diabetic coma 6. Patients with severe infections, before and after surgery, severe trauma 7. Patients with end-stage renal failure who are undergoing hemodialysis or peritoneal dialysis 8. Pregnant women or patients with potential pregnancy 9. Patients who research managers judged inappropriate as subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in HbA1c (NGSP value), glycoalbumin, blood glucose before and after treatment
- Secondary Outcome Measures
Name Time Method 1. Change before and after treatment of the following items; Urinary protein, urinary albumin and renal function (estimated glomerular filtration rate; eGFR) 2. Safety Event of the following side effects; Low blood sugar Urinary Tract Infections and Genital Infections Diabetic ketoacidosis Renal dysfunction Liver dysfunction fracture Malignant tumor Cardiac and cerebrovascular events Skin symptoms